Market Overview

Minomic Secures Key Patent in the United States and China


Minomic has received a Notice of Allowance for the company's patent
covering its cell surface antigen for the diagnosis of prostate cancer

Minomic International Ltd (Minomic), an immuno-oncology company
specializing in the commercialization and development of diagnostics and
therapeutics for solid tumors, including prostate, bladder and pancreas
has announced the grant of its patent ‘Cell surface prostate cancer
antigen for diagnosis' in the key global markets of the United States of
America and China.

Improved accuracy and sensitivity in prostate cancer diagnosis remains a
significant unmet medical need. Prostate cancer is one of the most
common cancers in the USA with a significant increase in incidence and
mortality also being observed in China. Substantial numbers of men would
benefit from the improvements in prostate cancer diagnosis that
Minomic's new technology could provide.

The Company has discovered that glypican-1 is a new marker for prostate
cancer with elevated levels detected in the body fluids or tissues of
prostate cancer patients. The invention provides compositions and
methods of detecting prostate cancer in the body fluids or tissues of
patients, where prostate cancer is detected by measuring, with other
markers, the level of glypican-1. The identified markers may also be
used in determining prognosis and monitoring response to treatment for
prostate cancer patients.

The Company said China and the US are the latest in the list of
countries where the patent has now been granted.

Minomic's CEO, Dr Brad Walsh, noted "Improving prostate cancer
diagnostics and ensuring appropriate treatments are used in a timely
fashion have the capacity to greatly decrease mortality and morbidity
associated with this disease. The granting of this patent in these key
markets also strengthens Minomic's IP portfolio enhancing the company's
business development efforts."

The scientific data behind Minomic's patent technology was recently
presented at the 3rd Global Summit on Precision Diagnosis and Treatment
of Prostate Cancer in Boston in August 2018, with further clinical data
recently submitted for publication.

About Minomic

Minomic is an Australian immuno-oncology company specialising in
therapeutics and diagnostics for solid tumours, including prostate,
bladder and pancreas. Minomic has developed the in vitro diagnostic test
called MiCheck® for the early detection of prostate cancer.
Minomic is preparing to globally launch MiCheck®, which has
been shown to be more than twice as specific as the existing gold
standard Prostate Specific Antigen (PSA) screening technology. This
means that MiCheck® delivers only 1.5 false positives from
every ten samples, compared to 6 false positive results in every 10
samples using the standard PSA test. The MiCheck® technology
uses Glypican-1, a recently identified biomarker and other biomarkers
never previously used in prostate cancer diagnosis. Minomic is
interested in partnerships or collaborations with larger
pharmaceutical/diagnostic global partners able to produce, register and
distribute MiCheck® and collaborate through registration and
commercialization of future diagnostic imaging and therapeutic
applications of the MIL-38 antibody for prostate cancer.

View Comments and Join the Discussion!